SCHEMBL2836710

SCHEMBL2836710

COc1cc(/C=C/c2ccc3c(C(C)=O)cc(Cl)c(O)c3n2)cc(O)c1O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIM1 P11309 7/20 0.60
▸ MEN1 O00255 6/20 0.49
▸ KMT2A Q03164 6/20 0.49
▸ RAB9A P51151 4/20 0.49
▸ MAPT P10636 2/20 0.49
▸ KDM4E B2RXH2 1/20 0.49
▸ LMNA P02545 1/20 0.49
▸ TLR9 Q9NR96 1/20 0.49
▸ NPC1 O15118 3/20 0.48
▸ CLK1 P49759 1/20 0.48
▸ DYRK2 Q92630 1/20 0.48
▸ GAA P10253 1/20 0.45
▸ MAPK1 P28482 1/20 0.45
▸ GFER P55789 1/20 0.45
▸ TDP1 Q9NUW8 1/20 0.45
▸ AGTR1 P30556 1/20 0.45
▸ POLB P06746 1/20 0.43
▸ OPRK1 P41145 1/20 0.43
▸ PDE4D Q08499 1/20 0.41
▸ ATM Q13315 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2836712 1.00 PIM1 (0.60) PIM1MEN1KMT2ARAB9AMAPT
SCHEMBL2834464 0.86 PIM1 (0.66) PIM1MEN1KMT2ARAB9AMAPT
SCHEMBL2834470 0.86 PIM1 (0.66) PIM1MEN1KMT2ARAB9AMAPT
SCHEMBL1559987 0.81 PIM1 (0.51) PIM1MEN1KMT2ARAB9AMAPT
SCHEMBL1559990 0.81 PIM1 (0.51) PIM1MEN1KMT2ARAB9AMAPT
SCHEMBL13321016 0.80 PIM1 (0.76) PIM1MEN1KMT2ARAB9AMAPT
SCHEMBL2835681 0.76 PIM1 (0.60) PIM1MEN1KMT2ARAB9AMAPT
SCHEMBL2835672 0.76 PIM1 (0.60) PIM1MEN1KMT2ARAB9AMAPT
SCHEMBL2834478 0.75 PIM1 (0.69) PIM1MEN1KMT2ARAB9AMAPT
SCHEMBL2834480 0.75 PIM1 (0.69) PIM1MEN1KMT2ARAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100120847-A1 STYRYLQUINOLINES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTIC USES BIOALLIANCE PHARMA (FR) 2010-05-13 — — US claimed
US-20110224242-A1 STYRLYQUINOLINES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTIC USES BIOALLIANCE PHARMA (FR) 2011-09-15 — — US disclosed
US-20110224242-A1 STYRLYQUINOLINES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTIC USES BIOALLIANCE PHARMA (FR) 2011-09-15 — — US disclosed
US-20100120847-A1 STYRYLQUINOLINES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTIC USES BIOALLIANCE PHARMA (FR) 2010-05-13 — — US disclosed
US-20100120847-A1 STYRYLQUINOLINES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTIC USES BIOALLIANCE PHARMA (FR) 2010-05-13 — — US disclosed
US-20100120847-A1 STYRYLQUINOLINES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTIC USES BIOALLIANCE PHARMA (FR) 2010-05-13 — — US disclosed
WO-2010010149-A1 STYRYLQUINOLINES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTIC USES BIOALLIANCE PHARMA (FR) 2010-01-28 — — WO disclosed
EP-2147912-A1 Styrylquinolines, their process of preparation and their therapeutic uses BioAlliance Pharma (FR) 2010-01-27 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100120847-A1 STYRYLQUINOLINES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTIC USES POLQ, PARP1, PARP14 PIM1 19/4885MEN1 4715/4885KMT2A 314/4885
US-20110224242-A1 STYRLYQUINOLINES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTIC USES POLQ, POLB, TYMP PIM1 35/4885MEN1 4799/4885KMT2A 550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback